In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Thomas Lund*, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold

*Corresponding author for this work

Research output: Contribution to journalComment/debateResearchpeer-review

14 Downloads (Pure)
Original languageEnglish
Article number65
JournalBlood Cancer Journal
Volume14
Number of pages5
ISSN2044-5385
DOIs
Publication statusPublished - 15. Apr 2024

Keywords

  • Bone Density Conservation Agents/therapeutic use
  • Bone Diseases/drug therapy
  • Bone Neoplasms
  • Bone and Bones
  • Diphosphonates/therapeutic use
  • Humans
  • Multiple Myeloma/drug therapy
  • Zoledronic Acid/therapeutic use

Cite this